Is there a rationale for therapeutic immunoadsorption in multiple sclerosis?

European Journal of Clinical Investigation

Volumn 35, Issue 8, 2005, Pages 467-468

  Berger, Thomas ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; IMMUNOGLOBULIN G ANTIBODY; MYELIN BASIC PROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN;

ANTIBODY SPECIFICITY; CENTRAL NERVOUS SYSTEM DISEASE; DEMYELINATION; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOADSORPTION; IMMUNOGENICITY; MULTIPLE SCLEROSIS; NOTE; PLASMAPHERESIS; PRIORITY JOURNAL;

ANTIBODIES; CENTRAL NERVOUS SYSTEM; HUMANS; IMMUNOSORBENT TECHNIQUES; MULTIPLE SCLEROSIS; MYELIN SHEATH; MYELIN-ASSOCIATED GLYCOPROTEIN;

EID: 23844463149     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2005.01546.x     Document Type: Note

References (13)

1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple Sclerosis. New Engl J Med 2000;343:938-52.
2. Lucchinetti C, Brück W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000;47:707-17.
3. Lassmann H, Brück W, Lucchinetti C. Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol Med 2001;7:115-21.
4. Storch MK, Piddlesden S, Haltia M, Ivanainen M, Morgan P, Lassmann H. Multiple sclerosis: in situ evidence for antibody- and complement mediated demyelination. Ann Neurol 1998;43:465-71.
5. Reindl, M., Linington, C., Brehm, U., Egg, R., Dilitz, E., Deisenhammer, F., Poewe, W., Berger, T. Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological disease: a comparative study. Brain 1999;122:2047-2056.
6. Berger, T. Multiple sclerosis. Antibodies as diagnostic and predictive markers of autoimmune diseases. Autoimmunity 2004;37:321-324.
7. Berger, T., Rubner, P., Egg, R., Schautzer, F., Ulmer, H., Mayringer I., Dilitz E., Deisenhammer F., Reindl M. Antimyelin antibodies as predictors for clinical definite multiple sclerosis in patients with a first demyelinating event. New Engl J Med 2003;146:181-197.
8. Brück, W., Neubert, K., Berger, T., Weber, J.R. Clinical, radiological, immunological and pathological findings in inflammatory CNS demyelination - possible markers for an antibody-mediated process. Multiple Sclerosis 2001;7:173-177.
9. Lennon, V. A., Wingerchuk, D. M., Kryzer, T. J., Pittock, S. J., Lucchinetti, C. F., Fujihara, K., Nakashima, I., Weinshenker, B. G. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004;364:2106-2112.
10. Weinshenker, B.G., O'Brien, P. C., Petterson, T. M., Noseworthy, J. H., Lucchinetti, C. F., Dodick, D. W., Pineda, A. A., Stevens, L. N., Rodriguez, M. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999;46:878-886.
11. Keegan, M., Pineda, A. A., McClelland, R. L., Darby, C. H., Rodriguez, M., Weinshenker, B. G. Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology 2002;58:143-146.
12. Moldenhauer, A., Haas, J., Wäscher, C., Derfuss, T., Hoffmann, K.-T., Kiesewetter, H., Salama, A. Immunoadsorption patients with multiple sclerosis: an open-label pilot study. Eur J Clin Invest 2005;35:516-523.
13. Weinstein, R. Therapeutic apheresis in neurological disorders. J Clin Apheresis 2000;15:74-128.